Abstract 1937P
Background
To clarify the clinicopathological features and clinical outcomes of histological subtypes of papillary thyroid carcinoma (PTC) in the pediatric and adolescent population treated at a single institution.
Methods
A total of 153 PTC patients ≤18 years of age who underwent initial surgery between 1979 and 2019 were investigated. The most common subtypes included classic PTC in 124 (81%), solid variant in 16 (10%), diffuse sclerosing variant in 7 (5%), and follicular variant in 6 (4%). Cause-specific survival (CSS) and disease-free survival (DFS) rates were calculated by the Kaplan–Meier method.
Results
There were 135 female and 18 male patients, with a mean age at the time of surgery of 16 (range, 8-18) years, and 5% (8 patients) were ≤10 years of age at diagnosis. At initial surgery, 49 patients (32%) had lymph node metastases diagnosed preoperatively (cN1), 16 (10%) had gross extrathyroidal extension (ETE), and 18 (12%) had lung metastases. Total thyroidectomy was performed in 55 (36%) patients, and 98 (64%) patients underwent less than total thyroidectomy. During a mean follow-up of 16 years, 3 patients died of their disease, and 34 patients had recurrent disease. The 30-year CSS rate was 97.2%, and the 30-year DFS rate was 65.0%. On univariate analysis, extensive ETE (p=0.001) and cN1 (p=0.003), but not histological subtype (p=0.21), were associated with disease recurrence. Extensive ETE and cN1 were identified as significant factors related to DFS on multivariate analysis (hazard ratio (HR) 5.2, confidence interval (CI) 1.9-12.4, p=0.0028; HR 3.2, CI.6-6.6, p=0.0021).
Conclusions
The prognosis of pediatric patients with PTC was good, but recurrence was common. In pediatric PTC, histological subtype did not affect survival and recurrence.
Clinical trial identification
Editorial acknowledgement
Funding
Has not received any funding.
Disclosure
All authors have declared no conflicts of interest.
Resources from the same session
1465P - Potential impact of APC mutation on survival via immune evasion through WNT signaling activation in HER2-positive gastric cancer treated with trastuzumab (tmab), nivolumab (nivo), and chemotherapy
Presenter: Takeru Wakatsuki
Session: Poster session 18
1468P - cGAS-driven inflammation in chromosomally unstable oesophagogastric adenocarcinoma
Presenter: Eileen Parkes
Session: Poster session 18
1469P - Development of an efficacy prediction model for concurrent chemoradiotherapy in esophageal squamous cell carcinoma using deep learning and multimodal data integration
Presenter: Xin Yang
Session: Poster session 18
1470TiP - Phase I trial of intraperitoneal infusion of GAIA-102 of NK-Like CD3-negative cells for gastric/pancreatic cancer
Presenter: Eiji Oki
Session: Poster session 18
1471TiP - MK-2870-015: A phase III study of trophoblast antigen 2 (TROP2)-directed antibody-drug conjugate (ADC) sacituzumab tirumotecan (sac-TMT) vs treatment of physician’s choice (TPC) for previously treated metastatic gastroesophageal adenocarcinoma (GEA)
Presenter: Zev Wainberg
Session: Poster session 18
1472TiP - Organ preservation with durvalumab-based immunotherapy in combination with chemoradiation as definitive therapy for early stage, cT1 and cT2N0, esophageal adenocarcinoma: A prospective, multicenter study of the FLOT-AIO Gastric Cancer Group – The IKF-057/ PRESTO trial
Presenter: Nils Homann
Session: Poster session 18
1473TiP - Neoadjuvant SOX combined with cadonilimab (AK104) for PD-L1 negative upper GC/GEJC patients
Presenter: Zhen Yuan
Session: Poster session 18
1474TiP - A randomized phase II study of disitamab vedotin (DV) plus toripalimab and chemotherapy versus DV plus toripalimab versus chemotherapy as perioperative treatment for HER2-expressing locally advanced gastric or gastroesophageal junction adenocarcinoma (GC/GEJ)
Presenter: Ziyu Li
Session: Poster session 18